Alkermes Plc (ALKS) Stock Price, Quote & News

Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed product...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 353 1 772 8000

Website: www.alkermes.com

Address:

Connaught House, 1 Burlington Road Dublin 4, Dublin, Ireland

ZacksResearch Jul. 30 at 3:48 PM

$ALKS just beat Q2 earnings — but here's the real driver 📈 Proprietary product sales jumped 14% year over year, helping offset declines in manufacturing and royalty revenue. See what this means for the next leg in ALKS 👉 https://www.zacks.com/stock/news/2639254/alkermes-q2-earnings-beat-estimates-proprietary-drugs-aid-sales?cid=sm-stocktwits-2-2639254-teaser-4814&ADID=SYND_STOCKTWITS_TWEET_2_2639254_TEASER_4814

0 · Reply

ZacksResearch Jul. 30 at 2:24 PM

$ALKS Q2 Earnings: Beating Estimates but Facing Challenges 📉 Alkermes reported EPS of 52 cents, topping the Zacks Consensus Estimate of 41 cents. Yet, total revenues fell 2.1% from the year-ago quarter to $390.7M, despite a strong performance from proprietary products like Vivitrol, Aristada, and Lybalvi. Discover the full earnings breakdown 👉 https://www.zacks.com/stock/news/2639254/alkermes-q2-earnings-beat-estimates-proprietary-drugs-aid-sales?cid=sm-stocktwits-2-2639254-body-4757&ADID=SYND_STOCKTWITS_TWEET_2_2639254_BODY_4757

0 · Reply

Estimize Jul. 29 at 10:18 PM

$ALKS reported 0.67 EPS and 390.66 revenue for Q2. http://www.estimize.com/intro/alks?chart=historical&metric_name=eps&utm_content=ALKS&utm

0 · Reply

JarvisFlow Jul. 29 at 12:30 PM

Needham updates rating for Alkermes ( $ALKS ) to Buy, target set at 45.

0 · Reply

LordHoven Jul. 29 at 11:08 AM

$ALKS https://www.prnewswire.co.uk/news-releases/alkermes-plc-reports-second-quarter-2025-financial-results-302515338.html

0 · Reply

StockHunter75 Jul. 28 at 1:32 PM

$ALKS load up

0 · Reply

Estimize Jul. 24 at 12:03 PM

Wall St is expecting 0.45 EPS for $ALKS Q3 [Reporting 10/22 BMO] http://www.estimize.com/intro/alks?chart=historical&metric_name=eps&utm_co

0 · Reply

ZacksResearch Jul. 22 at 6:04 PM

$ALKS down nearly 9% — even after positive trial results? 👀 Alixorexton met primary goals in narcolepsy type 1, but concerns around cataplexy data spooked investors. Full story behind the drop 👉 https://www.zacks.com/stock/news/2603277/alks-down-despite-positive-top-line-data-from-narcolepsy-study?cid=sm-stocktwits-2-2603277-teaser-3181&ADID=SYND_STOCKTWITS_TWEET_2_2603277_TEASER_3181

0 · Reply

ZacksResearch Jul. 22 at 1:30 PM

After a positive trial, why did $ALKS drop 8.8%? 🤔 Despite promising phase II results for alixorexton in narcolepsy treatment, only the 6 mg dose showed significant results in reducing cataplexy, possibly disappointing investors. Full analysis here 👉 https://www.zacks.com/stock/news/2603277/alks-down-despite-positive-top-line-data-from-narcolepsy-study?cid=sm-stocktwits-2-2603277-body-2998&ADID=SYND_STOCKTWITS_TWEET_2_2603277_BODY_2998

0 · Reply

Estimize Jul. 22 at 12:15 PM

Wall St is expecting 0.34 EPS for $ALKS Q2 [Reporting 07/29 BMO] http://www.estimize.com/intro/alks?chart=historical&metric_name=eps&utm_co

0 · Reply

Alkermes: A More Than Solid Quarter

Jul 29, 2025, 2:47 PM EDT - 6 days ago

Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 7:00 AM EDT - 6 days ago

Alkermes plc Reports Second Quarter 2025 Financial Results

Jul 21, 2025, 6:00 AM EDT - 14 days ago

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

Jul 15, 2025, 4:00 PM EDT - 20 days ago

Alkermes to Report Second Quarter Financial Results on July 29, 2025

Jun 2, 2025, 4:00 PM EDT - 2 months ago

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 2, 2025, 7:00 AM EDT - 2 months ago

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences

May 1, 2025, 4:31 PM EDT - 3 months ago

Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible

May 1, 2025, 11:21 AM EDT - 3 months ago

Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 3 months ago

Alkermes plc Reports First Quarter 2025 Financial Results

Apr 30, 2025, 7:00 AM EDT - 3 months ago

New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)

Apr 17, 2025, 4:00 PM EDT - 3 months ago

Alkermes to Report First Quarter Financial Results on May 1, 2025

Apr 2, 2025, 4:00 PM EDT - 4 months ago

Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:00 AM EDT - 4 months ago

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia

Mar 27, 2025, 7:00 AM EDT - 4 months ago

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder

Feb 26, 2025, 4:00 PM EST - 5 months ago

Alkermes to Participate in Upcoming Investor Conferences

Feb 25, 2025, 5:08 AM EST - 5 months ago

Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment

Feb 12, 2025, 2:40 PM EST - 6 months ago

Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 7:00 AM EST - 6 months ago

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

Feb 5, 2025, 4:00 PM EST - 6 months ago

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025

Jan 2, 2025, 4:00 PM EST - 7 months ago

Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 24, 2024, 9:58 AM EST - 9 months ago

Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth

Nov 11, 2024, 4:00 PM EST - 9 months ago

Alkermes to Participate in Two Upcoming Investor Conferences

Nov 7, 2024, 7:00 AM EST - 9 months ago

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

Oct 24, 2024, 1:04 PM EDT - 10 months ago

Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 7:00 AM EDT - 10 months ago

Alkermes plc Reports Third Quarter 2024 Financial Results

Oct 17, 2024, 4:00 PM EDT - 10 months ago

Alkermes to Report Third Quarter Financial Results on October 24, 2024

Sep 25, 2024, 8:00 AM EDT - 11 months ago

Alkermes to Host Investor Event to Review Orexin Portfolio Strategy

Sep 23, 2024, 7:00 AM EDT - 11 months ago

Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024

Sep 13, 2024, 7:00 AM EDT - 11 months ago

Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program

Aug 28, 2024, 4:00 PM EDT - 1 year ago

Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 22, 2024, 7:00 AM EDT - 1 year ago

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2

Jul 24, 2024, 2:20 PM EDT - 1 year ago

Alkermes plc (ALKS) Q2 2024 Earnings Call Transcript

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Alkermes plc Reports Second Quarter 2024 Financial Results

Jul 17, 2024, 4:00 PM EDT - 1 year ago

Alkermes to Report Second Quarter Financial Results on July 24, 2024

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024

May 28, 2024, 7:00 AM EDT - 1 year ago

Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024

May 17, 2024, 8:27 AM EDT - 1 year ago

The Bottom Fishing Club: Alkermes Has Great Value And Safety

May 14, 2024, 7:00 AM EDT - 1 year ago

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

May 2, 2024, 7:00 AM EDT - 1 year ago

Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk

May 1, 2024, 7:00 AM EDT - 1 year ago

Alkermes plc Reports First Quarter 2024 Financial Results

Apr 24, 2024, 7:00 AM EDT - 1 year ago

Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1

Apr 17, 2024, 4:00 PM EDT - 1 year ago

Alkermes to Report First Quarter Financial Results on May 1, 2024

Apr 9, 2024, 4:29 PM EDT - 1 year ago

Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data

Apr 9, 2024, 9:49 AM EDT - 1 year ago

Alkermes plc: Collecting The Fruits Of The 2023 Spinoff

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

Mar 7, 2024, 7:00 AM EST - 1 year ago

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

Feb 15, 2024, 3:08 PM EST - 1 year ago

Alkermes plc (ALKS) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 7:00 AM EST - 1 year ago

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024

ZacksResearch Jul. 30 at 3:48 PM

0 · Reply

ZacksResearch Jul. 30 at 2:24 PM

0 · Reply

Estimize Jul. 29 at 10:18 PM

$ALKS reported 0.67 EPS and 390.66 revenue for Q2. http://www.estimize.com/intro/alks?chart=historical&metric_name=eps&utm_content=ALKS&utm

0 · Reply

JarvisFlow Jul. 29 at 12:30 PM

Needham updates rating for Alkermes ( $ALKS ) to Buy, target set at 45.

0 · Reply

LordHoven Jul. 29 at 11:08 AM

$ALKS https://www.prnewswire.co.uk/news-releases/alkermes-plc-reports-second-quarter-2025-financial-results-302515338.html

0 · Reply

StockHunter75 Jul. 28 at 1:32 PM

$ALKS load up

0 · Reply

Estimize Jul. 24 at 12:03 PM

Wall St is expecting 0.45 EPS for $ALKS Q3 [Reporting 10/22 BMO] http://www.estimize.com/intro/alks?chart=historical&metric_name=eps&utm_co

0 · Reply

ZacksResearch Jul. 22 at 6:04 PM

0 · Reply

ZacksResearch Jul. 22 at 1:30 PM

0 · Reply

Estimize Jul. 22 at 12:15 PM

Wall St is expecting 0.34 EPS for $ALKS Q2 [Reporting 07/29 BMO] http://www.estimize.com/intro/alks?chart=historical&metric_name=eps&utm_co

0 · Reply

Quantumup Jul. 21 at 7:58 PM

Truist🏁 $CNTA Buy/$30 $ALKS $TAK HRMY $JAZZ $AXSM Leerink reiterated $CNTA at an Outperform rating and says, $ALKS' narcolepsy trial results are encouraging for $CNTA Truist and Leerink said in their research reports:

0 · Reply

DraftKing1 Jul. 21 at 3:36 PM

$ALKS 💪

0 · Reply

G101SPM Jul. 21 at 3:32 PM

CORRECTION $ALKS $26.23 not $26.13 printout: $ALKS $26.23 ask. BUY/REVISIT carries SPM 87.08 tag to $34.00 in midterm.

0 · Reply

G101SPM Jul. 21 at 3:25 PM

$ALKS $26.13 ask. BUY/REVISIT carries SPM 87.08 tag to $34.00 in midterm.

0 · Reply

Tendergem Jul. 21 at 3:23 PM

$ALKS Why is this down 10% today on positive news?

1 · Reply

BlakeCanyon50 Jul. 21 at 2:05 PM

$ALKS Caught it at -8%, 1,000 shares;

0 · Reply

briefingcom Jul. 21 at 12:34 PM

$ALKS: Alkermes Plc announces positive topline results from Vibrance-1 Phase 2 Study of once-daily Alixorexton in... https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20250721060904ALKS&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

JarvisFlow Jul. 21 at 12:00 PM

Needham updates rating for Alkermes ( $ALKS ) to Buy, target set at 45.

0 · Reply

Quantumup Jul. 21 at 11:07 AM

Stifel $ALKS Buy-$42: "We are reiterating our Buy rating on $ALKS on the back of positive top-line data for ALKS2680/"Alixorexton" in Narcolepsy Type-1. Bottom line: this study was widely expected to succeed given prior ph1b data in NT1 and broader support via Takeda. Even still, the results here look clearly positive with many key clinical endpoints hitting statistical significance at all doses, with the exception of cataplexy attacks which "numerically improved" at all doses and only hit a p-value at the mid-dose (we await details, but probably a powering/variability issue). On safety, the disclosure was fairly high level, but 95% of patients who participated in the trial entered the OLE which is always encouraging. The PR specifically noted no treatment-related signals in hepatic/renal parameters, vital signs or ophthalmic exams, but we'll need to wait for full data to see if there were any mild visual AEs at all -- we remain generally unconcerned though." $TAK $BIIB $AXSM JAZZ $CNTA

0 · Reply

BigSqueezeComing Jul. 21 at 11:03 AM

$ALKS Alixorexton, an oral orexin‑2 receptor agonist, showed substantial benefit in improving wakefulness, reducing sleepiness, and enhancing cognitive and fatigue outcomes — all with a favorable safety profile. These promising results have paved the way for Phase 3 development in narcolepsy type 1.

0 · Reply

BigSqueezeComing Jul. 21 at 11:02 AM

$ALKS The company plans to initiate a global Phase 3 program for NT1. Detailed data from the trial will be presented at the World Sleep Congress in Singapore (September 5–10, 2025). Two additional Phase 2 trials — Vibrance‑2 (NT2) and Vibrance‑3 (idiopathic hypersomnia) — are ongoing

0 · Reply

BigSqueezeComing Jul. 21 at 11:02 AM

$ALKS Over 95% of participants continued into the open-label extension phase, reflecting strong tolerability and retention

0 · Reply

Market Cap	4.38B
Revenue (ttm)	1.56B
Net Income (ttm)	367.07M
EPS (ttm)	N/A
PE Ratio	12.15
Forward PE	19.94
Profit Margin	23.57%
Debt to Equity Ratio	0.00

Volume	1,281,300
Avg Vol	1,931,280
Day's Range	N/A - N/A
Shares Out	165.08M
Stochastic %K	31%
Beta	0.47
Analysts	Strong Sell
Price Target	$40.81